A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
Clinical trial NCT04542070 · COMPLETED
Trial details
- NCT number
- NCT04542070
- Sponsor
- ViiV Healthcare
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-09
- Primary completion
- 2022-07-13
- Enrollment
- 687
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.